An update on Pay-for-Delay

So-called pay-for-delay cases are on their way to becoming a classic in the intersection of pharma and antitrust. As anything in this space, they are also somewhat political given the interest of public national health systems in lower prices. An opinion delivered this week by Advocate General Rantos to the European Court of Justice confirms … Continue reading An update on Pay-for-Delay →

The latest in pharma antitrust – and lessons for other industries

The pharmaceutical industry is a traditional focus for antitrust scrutiny, with regulators around the globe cracking down on practices that they think stifle competition and keep prices high. This post delves into recent developments in several jurisdictions, highlighting the different ways companies can get into antitrust trouble and summarising key lessons for businesses in all … Continue reading The latest in pharma antitrust – and lessons for other industries →

All eyes on pharma – also in the years to come?

When asked about current trends and industries in the focus of antitrust regulators worldwide, no expert’s shortlist is complete these days without a reference to the pharma industry. The Commission and other EU regulators apparently share that view and recently published a report on what has happened in this sector in the previous years. The … Continue reading All eyes on pharma – also in the years to come? →

Pharma and mergers – future alignment of multinational competition issues?

Co-authored by Carolin Goldbeck Those of you who follow this blog closely will remember that we touched upon the Pharmaceutical Merger Task Force, consisting of American and European regulators, in a short paragraph a while ago (here). Back then, we did not see any dramatic changes in the approach of competition authorities to assess mergers … Continue reading Pharma and mergers – future alignment of multinational competition issues? →